Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2104 (LINC02104) is a member of the long intergenic non-coding RNA gene family, defined by its lack of overlap with protein-coding genes, and functions principally by regulating gene expression at transcriptional and epigenetic levels[5][1]. LincRNAs such as LINC02104 are at least 200 nucleotides in length and are mostly transcribed from regions considered intergenic. These molecules typically act by interacting with chromatin remodeling complexes, modulating transcription factors, acting as molecular sponges for microRNAs, and influencing cell signaling pathways[1][5]. While many lincRNAs play important roles in disease pathogenesis, especially cancer or immune responses, there is currently no published data specifically implicating LINC02104 in these processes, and its detailed biological role remains uncharacterized.
None (no drugs; thus, no mechanism established)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2104 (LINC02104).